menuMenu
  • PASAULIS
  • KONTAKTAI
  • APIE MUS
    close
    • Terapinės sritys
      • - Diabetas
      • - Hepatitas C
  • ATSAKOMYBĖ
    close
    • Etika ir skaidrumas
      • - Atskleidimo kodeksas
  • MOKSLINIAI TYRIMAI
    close
    • Apie klinikinius tyrimus
    • Vystomų vaistinių preparatų kryptys
    • Apie vykstančius tyrimus
  • Vaistų sąrašas
  • Pranešti apie nepageidaujamą reakciją
  • APIE MUS navigate_next
    • Terapinės sritysnavigate_next
      • - Diabetas
      • - Hepatitas C
  • ATSAKOMYBĖ navigate_next
    • Etika ir skaidrumasnavigate_next
      • Atskleidimo kodeksas
  • MOKSLINIAI TYRIMAI navigate_next
    • Apie klinikinius tyrimus
    • Vystomų vaistinių preparatų kryptys
    • Apie vykstančius tyrimus
  • VAISTŲ SĄRAŠAS  
  • PRANEŠIMAS APIE NEPAGEIDAUJAMĄ REAKCIJĄ Į VAISTĄ  
  • KONTAKTAI  

Vakcinos

DAUGIAU

 
 

Hepatitas C

DAUGIAU

 
 

Diabetas

DAUGIAU

 
 

UAB “Merck Sharp & Dohme”
 
 

UAB Merck Sharp & Dohme
Kęstučio g. 59/27, 08124 Vilnius
Tel.nr. +370 5 278 0247
Faks.nr. +370 5 275 3646
El. paštas: msd_lietuva@merck.com
Įmonės kodas 111834114
PVM mokėtojo kodas LT118341113

 
 
 

Copyright © 2009-2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA. All rights reserved. This website is maintained by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
02/2019 LT-NON-00001

  • Privatumo politika
  • Naudojimosi sąlygos
  • Sveitainės žemėlapis
Cookie Preferences
Image: Circle Close Icon

Forward-Looking Statement ×
 

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.